Mammoth Biosciences disclosed preclinical nonhuman primate data for its lead in vivo gene‑editing program intended to permanently lower triglycerides and announced plans for a first clinical trial. The company reported monkey data demonstrating target engagement and durable triglyceride reductions, and said it will advance the program into human testing. Mammoth’s plan highlights rising activity among CRISPR pioneers to move metabolic and cardiometabolic targets into the clinic.